Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors

Sarah E. Fenton, Jeffrey Alan Sosman, Sunandana Chandra*

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy worldwide. Fortunately, it is often diagnosed while still localized and can be effectively treated with simple excision or Mohs micrographic surgery. However, a subset of patients are diagnosed with locally advanced, metastatic, or recurrent disease. As our understanding of the molecular pathogenesis of BCC and the Hedgehog signaling pathway has increased, Hedgehog inhibitors such as vismodegib and sonidegib have been introduced to improve the survival rates in this patient population. However, even with these advances, a significant proportion of patients will not respond to current therapies and remain at risk of developing either resistance during therapy or disease recurrence. This review paper discusses currently approved therapies in the treatment of localized, locally advanced, and metastatic BCC and the possible contribution that immune checkpoint inhibitors might add to the treatment of this malignancy.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalClinical Skin Cancer
Volume2
Issue number1-2
DOIs
StatePublished - Dec 1 2017

Fingerprint

Basal Cell Carcinoma
Immunotherapy
HhAntag691
Mohs Surgery
Therapeutics
Neoplasms
Survival Rate
Recurrence
Population

Keywords

  • BCC
  • Hedgehog inhibitors
  • Immune system
  • Locally advanced
  • Metastatic

ASJC Scopus subject areas

  • Oncology
  • Dermatology

Cite this

@article{0e97bbfd71124971994303e0880e58fd,
title = "Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors",
abstract = "Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy worldwide. Fortunately, it is often diagnosed while still localized and can be effectively treated with simple excision or Mohs micrographic surgery. However, a subset of patients are diagnosed with locally advanced, metastatic, or recurrent disease. As our understanding of the molecular pathogenesis of BCC and the Hedgehog signaling pathway has increased, Hedgehog inhibitors such as vismodegib and sonidegib have been introduced to improve the survival rates in this patient population. However, even with these advances, a significant proportion of patients will not respond to current therapies and remain at risk of developing either resistance during therapy or disease recurrence. This review paper discusses currently approved therapies in the treatment of localized, locally advanced, and metastatic BCC and the possible contribution that immune checkpoint inhibitors might add to the treatment of this malignancy.",
keywords = "BCC, Hedgehog inhibitors, Immune system, Locally advanced, Metastatic",
author = "Fenton, {Sarah E.} and Sosman, {Jeffrey Alan} and Sunandana Chandra",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.clsc.2017.11.001",
language = "English (US)",
volume = "2",
pages = "59--65",
journal = "Clinical Skin Cancer",
issn = "2405-8645",
publisher = "Elsevier Inc.",
number = "1-2",

}

Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. / Fenton, Sarah E.; Sosman, Jeffrey Alan; Chandra, Sunandana.

In: Clinical Skin Cancer, Vol. 2, No. 1-2, 01.12.2017, p. 59-65.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors

AU - Fenton, Sarah E.

AU - Sosman, Jeffrey Alan

AU - Chandra, Sunandana

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy worldwide. Fortunately, it is often diagnosed while still localized and can be effectively treated with simple excision or Mohs micrographic surgery. However, a subset of patients are diagnosed with locally advanced, metastatic, or recurrent disease. As our understanding of the molecular pathogenesis of BCC and the Hedgehog signaling pathway has increased, Hedgehog inhibitors such as vismodegib and sonidegib have been introduced to improve the survival rates in this patient population. However, even with these advances, a significant proportion of patients will not respond to current therapies and remain at risk of developing either resistance during therapy or disease recurrence. This review paper discusses currently approved therapies in the treatment of localized, locally advanced, and metastatic BCC and the possible contribution that immune checkpoint inhibitors might add to the treatment of this malignancy.

AB - Basal cell carcinoma (BCC) is the most commonly diagnosed malignancy worldwide. Fortunately, it is often diagnosed while still localized and can be effectively treated with simple excision or Mohs micrographic surgery. However, a subset of patients are diagnosed with locally advanced, metastatic, or recurrent disease. As our understanding of the molecular pathogenesis of BCC and the Hedgehog signaling pathway has increased, Hedgehog inhibitors such as vismodegib and sonidegib have been introduced to improve the survival rates in this patient population. However, even with these advances, a significant proportion of patients will not respond to current therapies and remain at risk of developing either resistance during therapy or disease recurrence. This review paper discusses currently approved therapies in the treatment of localized, locally advanced, and metastatic BCC and the possible contribution that immune checkpoint inhibitors might add to the treatment of this malignancy.

KW - BCC

KW - Hedgehog inhibitors

KW - Immune system

KW - Locally advanced

KW - Metastatic

UR - http://www.scopus.com/inward/record.url?scp=85037047021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037047021&partnerID=8YFLogxK

U2 - 10.1016/j.clsc.2017.11.001

DO - 10.1016/j.clsc.2017.11.001

M3 - Review article

VL - 2

SP - 59

EP - 65

JO - Clinical Skin Cancer

JF - Clinical Skin Cancer

SN - 2405-8645

IS - 1-2

ER -